Related Experiment Videos
Chemoembolization of hepatocellular carcinoma
Douglas E Ramsey1, Lily Y Kernagis, Michael C Soulen
1Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD 21287, USA.
Journal of Vascular and Interventional Radiology : JVIR
|October 2, 2002
Summary
Transcatheter arterial chemoembolization (TACE) is a key treatment for unresectable hepatocellular carcinoma (HCC). While TACE aims to control tumor growth and prolong life, its survival benefit requires further confirmation, especially compared to combined therapies.
Area of Science:
- Hepatobiliary Medicine
- Interventional Oncology
- Cancer Therapy
Background:
- Transcatheter arterial chemoembolization (TACE) is a primary treatment for unresectable hepatocellular carcinoma (HCC).
- TACE involves delivering chemotherapy and embolization agents to destroy tumor cells, aiming to preserve liver function.
Purpose of the Study:
- To evaluate the role and effectiveness of TACE in managing unresectable HCC.
- To assess the impact of TACE on patient survival and its potential as a palliative or neoadjuvant therapy.
Main Methods:
- Review of various TACE protocols and their application in treating diffuse or localized HCC.
- Analysis of outcomes from nonrandomized studies and randomized trials regarding TACE efficacy.
Main Results:
- TACE is a palliative treatment for HCC, not a cure, but can achieve tumor necrosis and growth control.
- Nonrandomized studies suggest survival benefits, but randomized trials have not consistently confirmed this.
- Combined TACE with other procedures like percutaneous ethanol injection shows improved survival rates comparable to surgical resection.
Conclusions:
- TACE is a valuable palliative option for unresectable HCC, improving outcomes when combined with other treatments.
- TACE can serve as neoadjuvant therapy or a bridge to liver transplantation.
- Further research is needed to clarify the definitive impact of TACE on patient survival.